Home › Soft Tissue Sarcoma › NCT03838718

REtroperitoneal SArcoma Registry: an International Prospective Initiative

REtroperitoneal SArcoma Registry (RESAR): Prospective Collection of Primary Retroperitoneal Sarcoma Patient's Data, Radiological and Pathological Material for the TransAtlantic Retroperitoneal Sarcoma Working Group

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

* primary RPS operated on in the participating center;
* age\>18 years at the time of the first treatment (pediatric patients can not be included)
* histological confirmed diagnosis according to the WHO criteria done on biopsy or surgical specimen by dedicated sarcoma pathologist;
* radiological examinations performed (contrast enhanced abdominal CT scan and/or MRI) prior to surgical resection;
* signed informed consent form;
* adequate compliance of the patients to the plan of follow-up

Exclusion Criteria:

* age\<18 years;
* recurrent tumor;
* benign retroperitoneal tumors;
* serious psychiatric disease that precludes informed consent or limits compliance;
* impossibility to ensure adequate follow-up

About the study

Surgery is currently the only potentially curative treatment modality for localized retroperitoneal sarcoma (RPS). Available studies regarding oncologic outcomes are mainly retrospective in nature, and RPS are recognized as a rare disease. Therefore, prospective analysis of high quality data is a top priority.

Primary Objectives of this study are:

* to prospectively collect standardized clinical data and radiological and pathological material from primary RPS patients treated with surgery at reference centers. * patient outcome will be evaluated in terms of overall survival (OS), disease-free survival (DFS), crude cumulative incidence (CCI) of local recurrence (LR) and distant metastasis (DM).

Secondary Objectives:

* to estimate the efficacy and safety of surgical treatment, including extended surgical approach to primary RPS; * to prospectively evaluate the impact of multimodality therapy, including radiation therapy and chemotherapy; * to identify clinical, radiological and pathological characteristics that may influence the oncological outcome or may be used as predictors of LR/DM/OS. These may be important biomarkers of disease; * to utilize collected pathological material for research collaborations.

Sponsor: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano · Participants: 2,000 · Started: Sep 1, 2016

Contact the study team

• Alessandro Gronchi, MD · Phone: +39022390
• Marco Fiore, MD · Phone: +392390

Official record on ClinicalTrials.gov — NCT03838718

Locations in the U.S.

Conditions

• Soft Tissue Sarcoma

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.